Mukherjee Sumit, Heng Henry H, Frenkel-Morgenstern Milana
Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel.
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Cancers (Basel). 2021 Aug 27;13(17):4328. doi: 10.3390/cancers13174328.
Gene fusions can give rise to somatic alterations in cancers. Fusion genes have the potential to create chimeric RNAs, which can generate the phenotypic diversity of cancer cells, and could be associated with novel molecular functions related to cancer cell survival and proliferation. The expression of chimeric RNAs in cancer cells might impact diverse cancer-related functions, including loss of apoptosis and cancer cell plasticity, and promote oncogenesis. Due to their recurrence in cancers and functional association with oncogenic processes, chimeric RNAs are considered biomarkers for cancer diagnosis. Several recent studies demonstrated that chimeric RNAs could lead to the generation of new functionality for the resistance of cancer cells against drug therapy. Therefore, targeting chimeric RNAs in drug resistance cancer could be useful for developing precision medicine. So, understanding the functional impact of chimeric RNAs in cancer cells from an evolutionary perspective will be helpful to elucidate cancer evolution, which could provide a new insight to design more effective therapies for cancer patients in a personalized manner.
基因融合可导致癌症中的体细胞改变。融合基因有可能产生嵌合RNA,其可产生癌细胞的表型多样性,并可能与癌细胞存活和增殖相关的新分子功能有关。嵌合RNA在癌细胞中的表达可能会影响多种与癌症相关的功能,包括凋亡缺失和癌细胞可塑性,并促进肿瘤发生。由于它们在癌症中的复发以及与致癌过程的功能关联,嵌合RNA被认为是癌症诊断的生物标志物。最近的几项研究表明,嵌合RNA可导致癌细胞对药物治疗产生抗性的新功能。因此,针对耐药性癌症中的嵌合RNA可能有助于开发精准医学。所以,从进化角度理解嵌合RNA在癌细胞中的功能影响将有助于阐明癌症进化,这可为以个性化方式为癌症患者设计更有效的治疗方法提供新的见解。